|Free Dividend Report|
|Stock Splits Calendar|
|KALV Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|Stock Message Boards|
KalVista Pharmaceuticals (KALV) has 1 split in our KALV split history database. The split for KALV took place on November 22, 2016. This was a 1 for 14 reverse split, meaning for each 14 shares of KALV owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 71.4285714285714 share position following the split.
When a company such as KalVista Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the KALV split history from start to finish, an original position size of 1000 shares would have turned into 71.4285714285714 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into KalVista Pharmaceuticals shares, starting with a $10,000 purchase of KALV, presented on a split-history-adjusted basis factoring in the complete KALV split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-35.37%|
|About KalVista Pharmaceuticals|
|KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co.'s product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). Co. has a portfolio of oral plasma kallikrein inhibitors and developed various drug candidates into clinical trials in order to create oral therapies for both HAE and DME. Co. has initiated a clinical study of KVD900 as a therapy for acute HAE attacks. Co. has also commenced a clinical trial of KVD001, its DME drug candidate. According to our KALV split history records, KalVista Pharmaceuticals has had 1 split.|
|KALV Split History Table|
|11/22/2016||1 for 14|
|Healthcare Stock Splits|
|KALV is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: KALV shares outstanding history